Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorOlivia Newton-John Cancer Research Institute
About this trial
This study is testing a new way of treating brain tumours using tiny radioactive beads called SIR-Spheres® (90Y-labelled Resin Microspheres). These microspheres are placed into the blood vessels that feed the tumour. The treatment gives off radiation inside the tumour to try to stop it from growing.
This type of treatment is called Selective Internal Radiation Therapy (SIRT), Transarterial Radioembolisation (TARE), or radioembolisation. It is already an accepted treatment for patients with liver cancer. In this study, we are testing if this treatment can be done safely in the brain and how well it works.
Eligibility criteria
Qualifiers
Age ≥18 years at the time of screening
Histomolecular diagnosis of IDH-wildtype glioblastoma (as per WHO 2021)
Prior treatment with radiotherapy and an alkylating agent
Presence of measurable disease on brain MRI, as defined by RANO 2.0 criteria
Disqualifiers
Multifocal glioma recurrence
Tumour located in the posterior fossa or involving/risking critical subcortical structures (e.g. thalamus, hypothalamus, basal ganglia, internal capsule, cerebral peduncle, midbrain, brainstem, or optic pathways)
Prior treatment with VEGF inhibitors
Prior re-irradiation for progressive or recurrent disease
Trial design
Treatments tested in this trial
- SIR-Spheres®
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Olivia Newton-John Cancer Research Institute
Lead sponsor
Austin Health
Collaborator
Source ClinicalTrials.gov